drug · small molecule
avutometinib potassium
Marketedupdated 3mo agoby $VSTM Verastem, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Phase 2 (across all indications), with 3 investigational indications.
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 9, 2027
182 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Dec 29, 2042formulationUS 11873296
- Dec 29, 2042formulationUS 12509450
- Sep 11, 2040method-of-use (U-4205)US 11517573
- Oct 29, 2038method-of-use (U-4196)US 11400090
- Aug 21, 2029compositionUS 79281093.0y
- Apr 17, 2028compositionUS 82474111.7y
- Feb 9, 2027compositionUS 7897792182d
FDA exclusivities (1)
- May 8, 2030NCENew Chemical Entity (5y)3.7y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that